AMJT Reports Near-Zero Revenue, $886K Impairment Drives Massive Loss in Q3
AMJT is trading near its 52-week low of $0.011 (0.0% above the low) on elevated volume (2.8× avg).
Summary
AMJ Global Technology reported extremely weak third-quarter 2025 results, with revenue of only $232, a negligible amount despite an increase from the prior year. The company's net loss significantly widened to $934,274, primarily driven by an $886,232 impairment charge. This substantial impairment, relative to the company's minimal revenue and micro-cap status, highlights severe financial distress. The company is attempting a strategic shift from mobile software to tech-based health treatments and pursuing related-party Medicare revenue-sharing, but current financial performance is dire. These results, summarized from the recent 10-Q filing, indicate significant operational challenges and raise concerns about the company's viability.
At the time of this announcement, AMJT was trading at $0.01 on OTC in the Technology sector, with a market capitalization of approximately $1.2M. The 52-week trading range was $0.01 to $5.95. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.